Literature DB >> 7865492

The effect of eradication of Helicobacter pylori upon the duodenal ulcer recurrence--a 24 month follow-up study.

N Y Kim1, H S Oh, M H Jung, S H Wee, J H Choi, K H Lee.   

Abstract

OBJECTIVES: To evaluate the effect of eradication of Helicobacter pylori(H.pylori) in the patients with duodenal ulcer(Du) upon the DU recurrence.
METHODS: This study was performed for 190 patients with DU. Four different methods-microscopy of Gram stained mucosal smear, specific culture, biopsy urease test, histology of H &E staining-were taken for identifying colonization of H. pylori before treatment, and for finding the eradication of H. pylori 4 weeks after completion of therapy in each treatment group (cometidine, omeprazole, colloidal bismuth subcitrate(CBS), CBS and metronidazole double therapy, CBS, metronidazole and amoxicillin triple therapy). To detect DU recurrence, the gastroscopy was performed at 6, 12, 18, and 24 months after therapy.
RESULTS: The eradication rate of the cimetidine group the omeprazole group, and the CBS group were 0%, 7.7%, 0%, respectively, and that of the double therapy group and the triple therapy group were 44.4% and 89.3%, respectively. Seventy three patients who were followed up for 2 years were categorized into two groups according to the eradication of H. pylori. The recurrence rate was 3.2% both in 1 year and 2 years later in the former group-one consisting of 31 patients with H. pylori eradicated, while the recurrence rate was 57.1% in 1 year and 78.6% in 2 years later, in the latter group-the other of 42 patients with H. pylori not eradicated.
CONCLUSION: The eradication of H. pylori in patients with DU reduces the recurrence of DU.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7865492      PMCID: PMC4532069          DOI: 10.3904/kjim.1994.9.2.72

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  40 in total

1.  Gastroenterologists in Sydney--histology and helicobacter.

Authors: 
Journal:  Lancet       Date:  1990-09-29       Impact factor: 79.321

2.  Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment.

Authors:  E A Rauws; W Langenberg; H J Houthoff; H C Zanen; G N Tytgat
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

3.  Helicobacter pylori eradication with doxycycline-metronidazole-bismuth subcitrate triple therapy.

Authors:  T J Borody; L L George; S Brandl; P Andrews; J Lenne; D Moore-Jones; M Devine; M Walton
Journal:  Scand J Gastroenterol       Date:  1992-04       Impact factor: 2.423

Review 4.  Campylobacter pyloridis, gastritis, and peptic ulceration.

Authors:  C S Goodwin; J A Armstrong; B J Marshall
Journal:  J Clin Pathol       Date:  1986-04       Impact factor: 3.411

5.  Effect of age on the frequency of active Campylobacter pylori infection diagnosed by the [13C]urea breath test in normal subjects and patients with peptic ulcer disease.

Authors:  D Y Graham; P D Klein; A R Opekun; T W Boutton
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226

6.  Helicobacter pylori infection treated with a tripotassium dicitrato bismuthate and metronidazole combination.

Authors:  J Weil; G D Bell; K Powell; A Morden; G Harrison; P W Gant; P H Jones; J E Trowell
Journal:  Aliment Pharmacol Ther       Date:  1990-12       Impact factor: 8.171

7.  Helicobacter pylori infection in pernicious anemia: a prospective controlled study.

Authors:  T L Fong; C P Dooley; M Dehesa; H Cohen; R Carmel; P L Fitzgibbons; G I Perez-Perez; M J Blaser
Journal:  Gastroenterology       Date:  1991-02       Impact factor: 22.682

8.  Campylobacter pylori and recurrence of duodenal ulcers--a 12-month follow-up study.

Authors:  J G Coghlan; D Gilligan; H Humphries; D McKenna; C Dooley; E Sweeney; C Keane; C O'Morain
Journal:  Lancet       Date:  1987-11-14       Impact factor: 79.321

9.  Double-blind randomized trial of bismuth subsalicylate and clindamycin for treatment of Helicobacter pylori infection.

Authors:  T U Westblom; E Madan; M A Subik; D E Duriex; B R Midkiff
Journal:  Scand J Gastroenterol       Date:  1992       Impact factor: 2.423

10.  Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication.

Authors:  T J Borody; P Cole; S Noonan; A Morgan; J Lenne; L Hyland; S Brandl; E G Borody; L L George
Journal:  Med J Aust       Date:  1989-10-16       Impact factor: 7.738

View more
  4 in total

1.  The presence of Helicobacter pylori in nonoperated duodenal ulcer patients compared to patients late after highly selective vagotomy.

Authors:  A Csendes; G Smok; M Coronel; R Avendaño; G Zenteno; H Cordova
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

2.  No protective role of Helicobacter pylori in the pathogenesis of reflux esophagitis in patients with duodenal or benign gastric ulcer in Korea.

Authors:  N Kim; S H Lim; K H Lee
Journal:  Dig Dis Sci       Date:  2001-12       Impact factor: 3.199

3.  Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial.

Authors:  Mohammad Hassan Emami; Mohammad Mehdi Saberfiroozi; Abbas Arj; Ali Reza Taghavi; Kamran Bagheri-Lankarani; Najaf Dehbashi; Mohammad Reza Fattahi; Mahvash Alizadeh; Mohammad Javad Kaviani; Rahim Bahri-Najafi; Bita Geramizadeh; Abbas Esmaeili
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

4.  Effect of eradication of Helicobacter pylori on the benign gastric ulcer recurrence--a 24 month follow-up study.

Authors:  N Kim; J H Oh; C G Lee; C Lim; K H Won; W R Choi; S H Lee; S H Lim; K H Lee
Journal:  Korean J Intern Med       Date:  1999-07       Impact factor: 2.884

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.